Xingqi Eye Medicine, Opangshi's stock price flashes creampie "myopia magic medicine" forbidden sale guess

Last Friday (June 24), Xingqi Eye medicine (SZ300573, the stock price was 136.02 yuan, and the market value of 11.983 billion) shares the stock price crashed into investors. After 10:30 on the same day, Xingqi's eye medicine stock price dived sharply, down 16.76%as of the closing of the market to 136.02 yuan/share. Xingqi's eye medicine plummeted and "connected" another eye -catching stock Opangshi (SZ300595, the stock price was 53.34 yuan, and the market value of 47.73 billion) fell.

Visual China Map

Because both companies have deployed "myopia magic drugs" Atropine's eye drops and sold through its medical institutions with Internet hospital qualifications, the stock price fluctuations have caused guessing "Adoppin eye drops will be banned by the Internet".

On June 24, both companies denied the rumor. Xingqi Eye medicine has not received a notice that has not received the sales restriction of Atropine's eye drops. Opangshi said that the company's Atropine eye drops have not yet carried out substantial sales, but it will be promoted as planned in the future.

"Daily Economic News" reporter noticed that although there is no domestic eye drops in China, the listing of eye fluids is officially approved to be listed, including the two companies, including the two companies, many companies have already seized Atto in advance through the "intra -hospital preparation+Internet hospital" model. Dripping eye fluid market.

Ophthalmology leading stock price diving sharply

On June 24, Xingqi Eye Medicine and Opangshi fell sharply. As of the close of the day, Xingqi eye medicine closed down 16.76%to 136.02 yuan/share, and the market value shrinkage about 2.4 billion yuan from the 23rd closing. Opang's vision set once fell nearly 10%, and finally closed 4.94%to 53.34 yuan/share.

On the platform and other platforms, investors discussed that the rise in stock prices such as Xingqi eye medicine or the previously issued "Regulations on the Implementation of the Drug Management Law (Revised Draft for the Draft Case)". This document stipulates that "third -party platform providers must not directly participate in drug network sales activities."

The weight of Xingqi Eye Medicine is in the research product -low -concentration Atto eye drops used to control adolescent myopia are being sold through Xingqi Ophthalmology Hospital with Internet hospital qualifications. Opangshi also announced in early June that Atropine's eye drops have obtained the qualifications of the hospital's preparation, and the company's hospitals have also obtained the Internet hospital license earlier. The stock price of the two companies fluctuated sharply at the same time, causing rumors about "Atropine's eye drops will be banned on the Internet as an in -hospital preparation."

On the morning of June 24th, the reporter of "Daily Economic News" called Xingqi Eye Pills as an investor. The other staff member said that in response to today's stock price trend, the company did not find the specific impact. No major things.

In response to the rumors of "Atropine's eye drops will be banned on the Internet", the other party said: "Regulations on the Implementation of the Drug Management Law" are currently only soliciting opinions and have not been formally implemented. Secondly Internet hospitals are used to sell drugs online. At present, the company's business model is no problem. "

Opangshi told the reporter of "Daily Economic News" that although the company has obtained the qualifications of the internal preparations of Atto's eye drops, it has not yet launched a substantial sales. The company is not clear about the specific reasons for the volatility of the secondary market. At present, the company's fundamentals are normal.

Both have denied that the sales of Atropine's Internet are limited. Is the stock price of two listed companies fell sharply? Investors have speculated that the stock price fluctuations are related to the notice of the National Random Supervision Plan for Random Supervision and Substation of the National Random Supervision of the National Random Inspection and Summary of the Health and Health Commission. The notice requires to increase the spot checks of medical institutions such as medical cosmetology, medical examination, health examination, oral, and myopia correction.

In this regard, Xingqi Eye Medicine said: "This notice cannot be said to have nothing to do with us, but the company's related businesses are conducted in accordance with the corresponding requirements. At present, the company has not received a notice of spot checks."

Dipping Drugs for bypassing the Internet

Xingqi Eye Medicine and Opangshi are on the ophthalmology track, and both are currently through the medical institutions with Internet hospital qualifications to sell adoph eye drops that have not been approved as preparations in the hospital.

Atto's eye drops are a Morine -alkaline receptor inhibitors that can relax the pupil sphincter and ciliary muscles, and the pupil dilation, increased intra -eye pressure, and paralysis of paralysis occur, which are mainly used for ductal optometry. In recent years, Adin's eye drops have become the "fragrant" of many eye medicine companies, mainly due to its control of adolescent myopia.

As early as 2005, Singapore and other places successively carried out research institutions to conduct research on Atropine's eye drops to delay the process of myopia. As of now, the clinical trials of Atropine's eye drops to control myopia are still in the preparation or development stage, and there is no low -concentration of Atropine eye drops in China.

In the Studies of Atto, Xingqi Eye Medicine ranked first echelon. According to the company's latest disclosure progress, Atropine's eye drops are in the phase III clinical stage. On the morning of June 24, the aforementioned staff of Xingqi Eye Medicine also told reporters that the clinical trials are still under normal development.

According to the expected of the Zhu Guoguang team of Soochow Securities, Ada Drip's eye drops of Xingqi Eye medicine are expected to become the first domestic period for being approved to be listed and obtained for a short market. According to Soochow Securities, the penetration rate of Atto's adolescents in myopia in 2025 is 0.67%, the market share of Xingqi eye medicine is 55%, and the number of medications is 450,000. /Box, 1/day), corresponding sales of 1.65 billion yuan. Behind the Eye Medicine Body, there are many eye medicine companies to deploy Adin's eye drops. Among them, Oukang Weiwan (HK1477, HK $ 11.8, and a market value of HK $ 7.868 billion) is also in the clinical stage of clinical III, Zhaofe Ophthalmology (HK6622, HK $ 4.13, market value of HK $ 2.238 billion), Hengrui Pharmaceutical (SH600276, stock price 33.52 yuan, market value of market value, market value 213.824 billion) and El Ophthalmology (SZ300015, the stock price of 41.86 yuan, and a market value of 226.951 billion) is also carried out atctoprotic drops or other drug research for preventing and controlling children's myopia.

It is worth noting that although it has not been approved, Xingqi Eye Medicine and Opangshi have taken the lead in achieving the sales of Atropine's eye drops.

In January of this year, "Daily Economic News" published an in -depth report entitled "A myopia" God Medicine "to support ten times the shares: Xingqi Eye Diabi bypass the Internet Harvesting Untitled Medicine". The reporter's investigation found that Xingqi Eye medicine was able to achieve the internal and external sales of Atto eye drops through online hospitals obtained by the internal preparation qualifications obtained by Atto eye drops and the qualifications obtained by the Xingqi Ophthalmology Hospital.

Since 2019, thanks to Atropine's eye drops, Xingqi eye medicine performance has begun to increase significantly. From 2019 to 2021, the company's net profit attributable to the mother was 162.79%, 145.11%and 121.31%year -on -year. The fastest -growing medical service sector revenue comes from Xingqi Ophthalmology Hospital, and 80 % of the income of the latter comes from the tube eye drops.

Multiple eye medicine companies copy path

After taste the sweetness, many companies in the same industry follow suit, including Opangshi. At the beginning of June this year, Opangshi announced that the holding subsidiary Hefei Kang's Ophthalmology Hospital obtained the "Registration and Approval of the Medical Institutional Preparation Registration" issued by the Anhui Provincial Drug Administration.

The company said that the registration was completed, allowing Hefei Kang Eye Hospital to start formulating and selling low -concentrations of Atto for children and adolescent myopia prevention and control to meet the clinical needs of this variety. Earlier, the company's hospitals have completed all practice registration procedures for the Internet hospital and obtained the qualifications of Internet hospitals. In an investor exchanges in May this year, Opangshi said that the sales of Atropine's eye drops will learn the sales experience of other companies.

Does this mean that Opangshi can also copy the market of Xingqi Eye medicine to seize the market of Atropine's eye drops? In this regard, Opangshi said to the reporter of "Daily Economic News" that the sales of Atropine's eye drops have not yet begun, but it will be advanced in the future. The demand population can obtain low -concentration Atto eye drops by providing services and distribution through online diagnosis and treatment through online diagnosis and treatment of Opangshi. The other party also emphasized that Internet hospitals are not the tools for the company to sell medicines and will not reduce the strictness of diagnosis and treatment.

The reporter also noticed that in addition to the two companies mentioned above, He's Ophthalmology (SZ301103, a stock price of 32.65 yuan, and a market value of 5.2 billion yuan) also answered investor questions in May this year that the company’s 0.01%sulfate oxic eye drops were 10 last year 10 last year 10 last year 10 last year 10 last year 10 last year 10 last year. Monthly obtained the registration approval of the medical institution preparations, which can be used in Shenyang He's and its Internet hospitals with prescriptions for practicing physicians.

In other words, a number of eye medicine companies that lay off Atropine's eye drops are copying the path of Xingqi eye medicine, using the internal preparation+Internet hospital model to "quench thirst" in the market.

Although this model "harvested" the market of Atropine's eye drops in advance, it implies the risk of violations. According to the Southern Daily: "In -hospital preparations can usually only be used in this medical institution. To circulate in the market, you need to obtain a national medicine quasi -word. Submitting the adjustment application. Selling in -hospital preparations in the form of online mailing may involve legal issues. "

Wang Kai, chief physician of the Ophthalmology Department of Peking University People's Hospital, told the reporter of "Daily Economic News" in January this year: "The medicines who have been approved to be listed are sold to the country, and even sold overseas, but the so -called intra -hospital preparations are the hospitals. The pharmaceutical department has the function of the distribution and sales, so we can only be sold in the hospital. "

Daily Economic News

- END -